Cristina M. Al-Matarneh, Natalia Simionescu, Alina Nicolescu, Mihaela Silion, Andrea Angeli, Niccolò Paoletti, Alessandro Bonardi, Paola Gratteri, Mariana Pinteala, Claudiu T. Supuran
{"title":"新型3-磺胺双尾吡咯-2- 1桥接分子作为有效的人类碳酸酐酶异构体抑制剂:设计、合成、分子模拟研究和MeWo、SK-BR-3和MG-63细胞系的抗癌活性","authors":"Cristina M. Al-Matarneh, Natalia Simionescu, Alina Nicolescu, Mihaela Silion, Andrea Angeli, Niccolò Paoletti, Alessandro Bonardi, Paola Gratteri, Mariana Pinteala, Claudiu T. Supuran","doi":"10.1021/acs.jmedchem.4c02586","DOIUrl":null,"url":null,"abstract":"Novel 3-sulfonamide pyrrol-2-one derivatives containing two sulfonamide groups were synthesized via a one-pot, three-component method using trifluoroacetic acid as a catalyst. Structural confirmation was achieved using spectroscopic techniques. The compounds were tested against four selected human carbonic anhydrase isoforms (hCA I, hCA II, hCA IX, and hCA XII). Most derivatives showed significant selectivity for hCA II, with 4h, 4i, 4n, 4k, and 4j demonstrating enhanced activity due to methoxy and hydroxy group patterns. Compound 4o exhibited strong dual selectivity for hCA II and hCA IX, while 4l was the most effective inhibitor of hCA XII. Additionally, 4e showed a preference for hCA XII inhibition. Biological evaluation on MeWo, SK-BR-3, and MG-63 cancer cells showed that compound <b>4l</b> was cytotoxic for MeWo cells without significantly affecting normal fibroblasts’ viability. Compounds <b>4e</b>, <b>4l</b>, and <b>4o</b> were shown to affect tumor cell viability in combination with doxorubicin in additional testing on MeWo cancer cells.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"25 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel 3-Sulfonamide Dual-Tail Pyrrol-2-one Bridged Molecules as Potent Human Carbonic Anhydrase Isoform Inhibitors: Design, Synthesis, Molecular Modeling Investigation, and Anticancer Activity in MeWo, SK-BR-3, and MG-63 Cell Lines\",\"authors\":\"Cristina M. Al-Matarneh, Natalia Simionescu, Alina Nicolescu, Mihaela Silion, Andrea Angeli, Niccolò Paoletti, Alessandro Bonardi, Paola Gratteri, Mariana Pinteala, Claudiu T. Supuran\",\"doi\":\"10.1021/acs.jmedchem.4c02586\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Novel 3-sulfonamide pyrrol-2-one derivatives containing two sulfonamide groups were synthesized via a one-pot, three-component method using trifluoroacetic acid as a catalyst. Structural confirmation was achieved using spectroscopic techniques. The compounds were tested against four selected human carbonic anhydrase isoforms (hCA I, hCA II, hCA IX, and hCA XII). Most derivatives showed significant selectivity for hCA II, with 4h, 4i, 4n, 4k, and 4j demonstrating enhanced activity due to methoxy and hydroxy group patterns. Compound 4o exhibited strong dual selectivity for hCA II and hCA IX, while 4l was the most effective inhibitor of hCA XII. Additionally, 4e showed a preference for hCA XII inhibition. Biological evaluation on MeWo, SK-BR-3, and MG-63 cancer cells showed that compound <b>4l</b> was cytotoxic for MeWo cells without significantly affecting normal fibroblasts’ viability. Compounds <b>4e</b>, <b>4l</b>, and <b>4o</b> were shown to affect tumor cell viability in combination with doxorubicin in additional testing on MeWo cancer cells.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"25 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-01-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.4c02586\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02586","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Novel 3-Sulfonamide Dual-Tail Pyrrol-2-one Bridged Molecules as Potent Human Carbonic Anhydrase Isoform Inhibitors: Design, Synthesis, Molecular Modeling Investigation, and Anticancer Activity in MeWo, SK-BR-3, and MG-63 Cell Lines
Novel 3-sulfonamide pyrrol-2-one derivatives containing two sulfonamide groups were synthesized via a one-pot, three-component method using trifluoroacetic acid as a catalyst. Structural confirmation was achieved using spectroscopic techniques. The compounds were tested against four selected human carbonic anhydrase isoforms (hCA I, hCA II, hCA IX, and hCA XII). Most derivatives showed significant selectivity for hCA II, with 4h, 4i, 4n, 4k, and 4j demonstrating enhanced activity due to methoxy and hydroxy group patterns. Compound 4o exhibited strong dual selectivity for hCA II and hCA IX, while 4l was the most effective inhibitor of hCA XII. Additionally, 4e showed a preference for hCA XII inhibition. Biological evaluation on MeWo, SK-BR-3, and MG-63 cancer cells showed that compound 4l was cytotoxic for MeWo cells without significantly affecting normal fibroblasts’ viability. Compounds 4e, 4l, and 4o were shown to affect tumor cell viability in combination with doxorubicin in additional testing on MeWo cancer cells.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.